Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06738056 · ClinicalTrials.gov registry record
Nerivio Long-term Usage in Patients With Migraine
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 244
- Enrollment target
NCT06738056: Completed study, sponsored by Theranica.
NCT06738056 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 244 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06738056 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 244 participants
- Enrollment target
Study Summary
This is a post-marketing real-world evidence study investigates long-term treatment with the Remote Electrical Neuromodulation (REN) wearable Nerivio device over 3 consecutive years in patients with migraine.
Primary Outcome
No clinically meaningful change in treatment intensity between the years (defined as change of less than 2.5 of treatment intensity units between consecutive years).
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2024-12-01 |
| Est. Completion | 2024-12-22 |
What the finished NCT06738056 record still lists
NCT06738056 is an observational study that tracks outcomes without assigning an intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT06738056 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06738056 about?
NCT06738056 is a clinical study titled "Nerivio Long-term Usage in Patients With Migraine". This is a post-marketing real-world evidence study investigates long-term treatment with the Remote Electrical Neuromodulation (REN) wearable Nerivio device over 3 consecutive years in patients with migraine.
What is the current status of trial NCT06738056?
This trial is currently completed. The enrollment target is 244 participants. The study started on 2024-12-01. Estimated completion is 2024-12-22.
What interventions are being tested in trial NCT06738056?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT06738056?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI